Question 1

What specific benefits do you think VX-147 could provide for my condition?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis clinical trial (NCT04340362). Contact the study team or your healthcare provider for specific answers.

Question 2

Are there any potential side effects I should be aware of?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis clinical trial (NCT04340362). Contact the study team or your healthcare provider for specific answers.

Question 3

How does this treatment compare to other options available for FSGS?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis clinical trial (NCT04340362). Contact the study team or your healthcare provider for specific answers.

Question 4

What will the treatment schedule look like, and how often will I need to come in for visits?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis clinical trial (NCT04340362). Contact the study team or your healthcare provider for specific answers.

Question 5

Are there any additional tests or monitoring required during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis clinical trial (NCT04340362). Contact the study team or your healthcare provider for specific answers.

Question 6

What happens if I experience side effects or my condition worsens during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis clinical trial (NCT04340362). Contact the study team or your healthcare provider for specific answers.

What this study is about